Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 4-Year Follow-up, Blinded-Outcomes Trial of Subjects Having Received Stannsoporfin or Placebo in Clinical Trial 64,185-202

NCT02033096 is registered in ClinicalTrials.gov with InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company as lead sponsor.

NCT NCT02033096
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02033096 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 4-Year Follow-up, Blinded-Outcomes Trial of Subjects Having Received Stannsoporfin or Placebo in Clinical Trial 64,185-202
Lead sponsor
InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
Phase
Observational
Overall status
Completed
Start date
October 20, 2008
Completion date
November 9, 2015
Enrollment
42 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

jaundice, neonatal hyperbilirubinemia